# OnCo record nct03262935 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03262935/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03262935", "NCT03262935" ;
  schema:name "SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer"@en ;
  schema:description "A phase 3 trial of Trastuzumab duocarmazine, Lapatinib, Capecitabine, Trastuzumab, Vinorelbine and Eribulin in Breast cancer, run by Byondis B.V., completed."@en ;
  schema:url <https://onco.cc/trials/nct03262935/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03262935> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-duocarmazine/>, <https://onco.cc/drugs/lapatinib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/vinorelbine/>, <https://onco.cc/drugs/eribulin/> ;
  onco:companies <https://onco.cc/companies/byondis/> .